Ustekinumab
Ustekinumab is a therapeutic monoclonal antibody used in immune-mediated inflammatory diseases.
Ustekinumab is a therapeutic monoclonal antibody used in immune-mediated inflammatory diseases. It is described in the recent literature as an interleukin-12/-23 antagonist, reflecting its role in modulating cytokine signaling pathways that contribute to chronic inflammation. Clinically, it is approved for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, and it is also being evaluated in pediatric inflammatory bowel disease.
Biologically, ustekinumab is significant because it targets the shared p40 subunit of interleukin-12 and interleukin-23, thereby reducing downstream inflammatory signaling implicated in psoriasis and inflammatory bowel diseases. Its established clinical use has made it a reference molecule in comparative effectiveness studies, safety analyses, pediatric treatment research, and antibody engineering efforts focused on IL-23 biology.
Where the papers sit
10 papers from the last 6 months study ustekinumab directly · updated from PubMed 3 Nov 2026
Study type 0 clinical trials · 1 observational · 3 human data · 6 unclassified
Themes 3 themes · 1 new direction
-
Crohn's Disease Biologic Therapy
Crohn's disease treatment is moving toward individualized biologic selection and optimization in real-world practice. Ustekinumab is evaluated against anti-TNF agents and vedolizumab for remission, safety, quality of life, and durability. Repeated intravenous weight-based maintenance, partial enteral nutrition, and improved autoinjector usability address loss of response and treatment burden. Comparative effectiveness remains dependent on prior biologic exposure and patient selection.
6 papers · 60%
-
Biosimilars in Inflammatory Bowel Disease
Biosimilars are moving from initial uncertainty toward routine use in inflammatory bowel disease. Switching from originator biologics, including ustekinumab, is being assessed through clinical remission, safety, and treatment persistence. Comparisons with adalimumab and infliximab support broadly similar outcomes, while pediatric benefit-risk evidence remains thinner than adult evidence. Long-term switching outcomes and disease-specific monitoring remain open questions.
3 papers · 30%
-
Beta-Cell Function Monitoring
Diabetes monitoring is moving toward repeated minimally invasive measurement of C-peptide. Serial dried blood spot sampling detects early preservation of β-cell function, whereas the urine C-peptide-to-creatinine ratio does not. Mixed-meal tolerance testing provides the comparator for assessing assay performance and durability. Whether dried blood spot testing can support broader long-term trials and routine monitoring remains open.
1 papers · 10%
Ustekinumab is investigated as an intervention in recent-onset type 1 diabetes rather than as therapy for inflammatory bowel disease or other established indications
The USTEKID trial in adolescents with recent-onset type 1 diabetes uses ustekinumab in an interventional study assessing preservation of β-cell function, with dried-blood-spot and urine C-peptide measurements evaluated against the mixed-meal tolerance test 42118600May. This places ustekinumab in a new disease and investigational role outside the set’s predominant use of it as treatment for Crohn’s disease, ulcerative colitis, psoriasis, or related inflammatory conditions.
Papers
The 10 papers from the last 6 months that study ustekinumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Crohn's Disease Biologic Therapy (6)
- Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn's disease: Analysis from a real-world cohort. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 3 Oct 2026 PMID 42829277
- Synergistic effects of partial enteral nutrition combined with Ustekinumab in induction and maintenance therapy for Crohn's disease: Real-world experience from a multicentre cohort. Clinical nutrition (Edinburgh, Scotland) · 10 Jul 2026 PMID 42430976
- Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group. Alimentary pharmacology & therapeutics · 10 Jul 2026 PMID 42426976
- Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany. Alimentary pharmacology & therapeutics · 15 Jun 2026 PMID 42298310
- Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab. Drug delivery · 29 May 2026 PMID 42212686
- Repeated intravenous weight-based ustekinumab maintenance as an optimization strategy for Crohn's disease patients with loss of response to standard therapy. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 16 May 2026 PMID 42142993
Biosimilars in Inflammatory Bowel Disease (3)
- Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization. Revista espanola de enfermedades digestivas · 26 Oct 2026 PMID 42929266
- Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 27 Aug 2026 PMID 42660257
- Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183
Beta-Cell Function Monitoring (1)
- Serial Dried Blood Spot C-Peptide Sampling, but Not Urine C-Peptide-to-Creatinine Ratio, Detects Early Preservation of β-Cell Function in New-Onset Type 1 Diabetes: Experience From the USTEKID Trial. Diabetes care · 12 May 2026 PMID 42118600
By study type
Observational studies and case reports (1)
- Repeated intravenous weight-based ustekinumab maintenance as an optimization strategy for Crohn's disease patients with loss of response to standard therapy. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 16 May 2026 PMID 42142993
Human data, design not indexed (3)
- Synergistic effects of partial enteral nutrition combined with Ustekinumab in induction and maintenance therapy for Crohn's disease: Real-world experience from a multicentre cohort. Clinical nutrition (Edinburgh, Scotland) · 10 Jul 2026 PMID 42430976
- Human factors validation study of a disposable autoinjector (Bmab 1200 autoinjector) for subcutaneous delivery of Ustekinumab. Drug delivery · 29 May 2026 PMID 42212686
- Serial Dried Blood Spot C-Peptide Sampling, but Not Urine C-Peptide-to-Creatinine Ratio, Detects Early Preservation of β-Cell Function in New-Onset Type 1 Diabetes: Experience From the USTEKID Trial. Diabetes care · 12 May 2026 PMID 42118600
Unclassified: not yet indexed with MeSH (6)
- Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization. Revista espanola de enfermedades digestivas · 26 Oct 2026 PMID 42929266
- Comparative effectiveness and safety of first-line anti-TNF, vedolizumab, and ustekinumab in biologic-naïve Crohn's disease: Analysis from a real-world cohort. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 3 Oct 2026 PMID 42829277
- Clinical Outcomes After Ustekinumab Biosimilar Switching in Crohn's Disease: the USBIOS IG-IBD Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 27 Aug 2026 PMID 42660257
- Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group. Alimentary pharmacology & therapeutics · 10 Jul 2026 PMID 42426976
- Benefit-risk balance of advanced therapies in pediatric inflammatory bowel disease: evidence and gaps versus adults. Inflammatory bowel diseases · 23 Jun 2026 PMID 42334183
- Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany. Alimentary pharmacology & therapeutics · 15 Jun 2026 PMID 42298310
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-07-11. Last written: 2026-08-29 by GPT. Drafted by language models from published abstracts; not medical advice.